International Journal of Clinical Research

Objective To study the clinical value of continuous intravenous injection of recombinant human endostatin injection combined with window single drug docetaxel chemotherapy in the second-line treatment of advanced lung squamous cell carcinoma. Methods: Sixty patients with advanced lung squamous cell carcinoma admitted to our hospital from September 2018 to June 2020 were selected and divided into study group, control group 1 and control group 2 by random number table method, with 20 patients in each group. Control group 1 was given single drug docetaxel, control group 2 was given Docetaxel injection combined with platinum (cisplatin 75mg/m2, carboplatin AUC=5/6, Nedaplatin 75mg/m2) chemotherapy, and the study group was given continuous intravenous pumping of recombinant human endostatin 30mg/d for 7 days. At the same time, docetaxel injection 75mg/m2 chemotherapy was given in the window period (day 4).The therapeutic effect, incidence of adverse reactions and survival rate at different stages of follow-up were statistically compared among the three groups. Results: The efficacy evaluation results of the study group indicated that the objective effective rate and disease control rate were higher than those of control group 1 and control group 2, the difference was statistically significant (P < 0.05).The incidence of adverse reactions in study group during treatment was lower than that in control group 1 and control group 2, and the difference was statistically significant (P < 0.05). The survival rate of the study group was higher than that of control group 1 and control group 2 at 6, 12 and 18 months after 28-day safe follow-up, and the difference was statistically significant (P < 0.05). Conclusion: Continuous intravenous infusion of recombinant human endostatin injection combined with window single drug docetaxel chemotherapy can improve the efficacy and safety of second-line treatment for advanced lung squamous cell carcinoma, and prolong the survival of patients.

Lung squamous cell carcinoma; Second-line treatment; Recombinant human endostatin; The window period; Docetaxel